Statistics indicate that approximately 20% of breast cancer patients exhibit overexpression of human epidermal growth factor receptor 2 (HER2), which is associated with adverse prognosis, an aggressive phenotype, and shorter OS (6). The gene discussed is ERBB2; the disease is breast cancer.